IP Library Granted Patent US 9,782,437
Granted Patent B2
US 9,782,437 · App. 14/448,618 · Granted Oct 10, 2017

Methods and compositions for targeted cleavage and recombination

Inventors: Michael C. Holmes (Richmond, CA); Fyodor Urnov (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
A61K35/12C07K14/43595C07K14/4717C07K14/715C12N9/14C12N9/22C12N15/62C12N15/85C07K2319/00C07K2319/09C07K2319/81C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,782,437
App. No.
14/448,618
Granted
Oct 10, 2017
Kind
B2
Abstract

Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.

Claims (12)

1. An isolated cell comprising

(i) an exogenous non-naturally occurring nuclease comprising

first and second heterodimerizing FokI cleavage domains, wherein one of the first and second cleavage domains comprises a substitution mutation of amino acid 490 of the wild-type dimerization interface, and

a zinc finger DNA-binding protein that is heterologous to the first and second cleavage domains, wherein the zinc finger DNA-binding protein binds to a sequence in an HLA gene, and

(ii) an inactivated endogenous HLA gene, wherein the endogenous HLA gene comprises on or more nucleotide insertions, deletions or substitutions such that it is inactivated.

2. The cell of claim 1 , wherein the cell is a stem cell.

3. The cell of claim 1 , wherein the cell further comprises a transgene.

4. A method of grafting a cell into a host, the method comprising, administering a cell according to claim 1 to the host.

5. The method of claim 4 , where the cell further comprises a transgene.

6. The method of claim 4 , wherein the inactivated HLA gene encodes a Major Histocompatibility Complex (MHC) class 1 protein.

7. The method of claim 6 , wherein the inactivated HLA gene encodes an MHC β subunit gene (β2 microglobulin).

8. The method of claim 6 , wherein the cell is a stem cell.

Assignments (1)
CHANGE OF NAME Recorded May 19, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 042506/0290 →
Continuity (10)
Continuation 13837027 · Mar 15, 2013
Continuation 12804234 · Jul 16, 2010
Continuation 10912932 · Aug 6, 2004
Provisional Application 60493931 · Aug 8, 2003
Provisional Application 60518253 · Nov 7, 2003
Provisional Application 60530541 · Dec 18, 2003
Provisional Application 60542780 · Feb 5, 2004
Provisional Application 60556831 · Mar 26, 2004
Provisional Application 60575919 · Jun 1, 2004
Related Publication 20140369980A1 · Dec 18, 2014